KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) EBIT (2018 - 2025)

Historic EBIT for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$54.8 million.

  • BioNTech SE's EBIT fell 57547.68% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 111.18%. This contributed to the annual value of -$1.4 billion for FY2024, which is 28906.84% down from last year.
  • Per BioNTech SE's latest filing, its EBIT stood at -$54.8 million for Q3 2025, which was down 57547.68% from -$567.2 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's EBIT ranged from a high of $5.6 billion in Q3 2021 and a low of -$1.0 billion during Q2 2024
  • For the 5-year period, BioNTech SE's EBIT averaged around $1.6 billion, with its median value being $566.2 million (2023).
  • Per our database at Business Quant, BioNTech SE's EBIT surged by 184653558396.13% in 2021 and then plummeted by 57547.68% in 2025.
  • Quarter analysis of 5 years shows BioNTech SE's EBIT stood at $5.4 billion in 2021, then crashed by 37.51% to $3.4 billion in 2022, then plummeted by 83.15% to $566.2 million in 2023, then crashed by 71.95% to $158.8 million in 2024, then tumbled by 134.53% to -$54.8 million in 2025.
  • Its EBIT stands at -$54.8 million for Q3 2025, versus -$567.2 million for Q2 2025 and -$561.8 million for Q1 2025.